Tag:
Herb Kohl
Latest Headlines
Latest Headlines
Lawmakers seek recall info from Medtronic, 4 others
Three U.S. senators have fired off investigative letters to 5 devicemakers seeking information on how the companies conduct post-market surveillance, as well as on how they manage recalls when a...
CBO: Pay-to-delay ban could save $4.8B
The Congressional Budget Office has analyzed the proposed pay-to-delay ban, and its money-saving estimate comes in at almost $5 billion. According to CBO, the Preserve Access to Affordable Generic
Kohl backs drug-spending cuts focused on Medicare Part B
As promised, Sen. Herb Kohl (D-WI) has put forth a bill that would cut U.S. drug spending by billions of dollars over the next decade. It's not exactly a death by a thousand cuts, but the 6 new
GAO: FDA doesn't oversee device recalls properly
A GAO report has determined the FDA hasn't routinely analyzed recall data to determine whether there are systemic problems underlying trends in device recalls. Senators Chuck Grassley (R-IA) and Herb
Senate tacks 'pay-for-delay' ban onto spending bill
Last week, the drug business got a reprieve on a proposed "pay-for-delay" ban when the Senate tossed the measure from a war-funding bill. But that reprieve was only temporary. Yesterday, the Senate
Why do Americans pay more for their meds?
Why do Americans pay so much for their pharmaceuticals? That's the question posed by Sen. Herb Kohl, a Democrat and chairman of the Senate Special Committee on Aging, who has written to the world's
Pay-for-delay ban dropped from reform bill
Healthcare reform just started to look better for pharma: That ban on pay-for-delay deals has been dropped from the legislation. The provision would have barred patent settlements in which generics
Doc disclosure gets boost from AZ, Merck
Drugmakers are climbing on the disclosure bandwagon. AstraZeneca and Merck have come out in favor of a bill requiring pharma and device-makers to report their payments to doctors, joining Eli
Senate probes Zetia schmooze plan
Earlier this week sales-rep forums were abuzz with a new promo push by Schering-Plough: The so-called 49 Plan, a seven-week wine-and-dine rush to turn the tide on Zetia.
Sens. would dispatch pharma anti-reps
Should the feds send out their own pharma reps? Wednesday, the Senate Special Committee on Aging will convene to discuss "academic detailing," which is essentially a straight talk express for pharma.
